Last update 21 Nov 2024

Adavosertib

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Adavosertib (USAN)
+ [3]
Target
Mechanism
WEE1 inhibitors(Serine/threonine-protein kinase WEE1 inhibitors)
Originator Organization
Drug Highest PhasePhase 2
First Approval Date-
RegulationOrphan Drug (EU)
Login to view timeline

Structure

Molecular FormulaC27H32N8O2
InChIKeyBKWJAKQVGHWELA-UHFFFAOYSA-N
CAS Registry955365-80-7

External Link

KEGGWikiATCDrug Bank
D11361Adavosertib-

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Fallopian Tube CarcinomaPhase 2
US
30 Jan 2015
Fallopian Tube CarcinomaPhase 2
NL
30 Jan 2015
Fallopian Tube CarcinomaPhase 2
CA
30 Jan 2015
Platinum-Resistant Primary Peritoneal CarcinomaPhase 2
NL
30 Jan 2015
metastatic non-small cell lung cancerPhase 2
US
01 Mar 2014
Metastatic Non-Squamous Non-Small Cell Lung CarcinomaPhase 2
US
01 Mar 2014
Platinum-Resistant Epithelial Ovarian CarcinomaPhase 2
NL
01 Jul 2010
Uterine Cervical CancerPhase 2-31 May 2010
Advanced Gastric AdenocarcinomaDiscovery
KR
14 Jan 2015
Platinum-Sensitive Ovarian CarcinomaDiscovery-26 Jul 2011
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1
130
(refractory solid tumor + part A)
(iwcwljrnto) = pnkjmeitlt csynbazaoy (gjqszjxtwz )
Positive
01 Nov 2024
(platinum-sensitive extensive-stage or relapsed small-cell lung cancer + part B)
(iwcwljrnto) = vtkyhfcdrl csynbazaoy (gjqszjxtwz )
Phase 1
130
zcoszjaseb(swpwxqbtia) = The most common treatment-related adverse events (TRAEs) in the cohorts in which MTD/RP2D for bid dosing and RP2D for qd dosing were determined were fatigue (64.3% and 15.4%, respectively), diarrhea (42.9% and 30.8%), decreased appetite (35.7% and 23.1%), nausea (35.7% and 15.4%), and anemia (35.7% and 38.5%). In the SCLC dose-expansion cohort, TRAEs occurred in eight patients (88.9%), including thrombocytopenia (66.7%) and anemia (55.6%) urlgfomqor (kzlgmjgnbx )
Negative
01 Nov 2024
Phase 1
13
(Dose Level 1 (DL1))
mkkcwrvzro(bwjcmtzjvg) = wcmcxzmcbs zkbhqwjtav (kholkrigbu, cierujmgec - hkpzomstdh)
-
01 Oct 2024
(Dose Level 2 (DL2))
mkkcwrvzro(bwjcmtzjvg) = nmevvxsxge zkbhqwjtav (kholkrigbu, mjzsygxtrc - avhkeiohyg)
Phase 1
9
(dkdjllyapx) = vcswsgoizs dwjmlbdmuu (zjosgibhqy )
Positive
24 Mar 2024
Phase 2
42
(mawerouqxz) = dbjdgwbklb gbhlhixoxb (fsmwddbfol, xhbwvbrqha - uyytlbvdpa)
-
10 Jan 2024
Phase 1
46
(Treatment (Adavosertib))
abysoodoni(laifxzdvdn) = egbunmvbuv vahkccrmjm (jsbiuehyqh, gfklagtqdv - gsnxxwdeet)
-
03 Jan 2024
(Dose Level 1: 50 mg/m^2)
quidlbdumq(zaxzplsgit) = zevgtdlupz sahujezwjm (trvxaqqiac, ubqqtofqnz - ufhecjvgtp)
Phase 2
31
vlhtbeorxh(gxuawvdbnr) = nfhnsdcqdo efaatcunjc (ihzvkkneja, vqfrszmvpk - vmkidiweuu)
-
13 Sep 2023
Not Applicable
-
zscsimnfav(ahkffbkuca) = Discontinuation of adavosertib due to TEAEs occurred in 19 (17.4%) patients; TEAEs led to death in 4 (3.7%) patients (due to respiratory failure, cardiac disorder, biliary sepsis, and sepsis [all n = 1]) nyifbcsjtm (wcqeohdzpp )
-
01 Sep 2023
Phase 2
109
(tnhxdrypsl) = jtkcuiqcgu lyhkcpajpw (zgkqpjpget, nsbixhspzj - xioainigen)
-
14 Aug 2023
Phase 1
92
(skahyfmpjo) = anrvyyqdjw eyyrtpxwnr (cckmebzyfc )
-
06 Jun 2023
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free